Physician profile
Cheryl Young
NPI 1639158652
$2,667.56
in general payments reported to CMS, 2019-2025
24 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $602 · 2022: $681 · 2023: $549 · 2024: $480 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,283.97 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.41 | 2021-2024 | |
| Janssen Biotech, INC. | $395.71 | 2021-2024 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $232.62 | 2021-2025 | Blu-U, Odomzo |
| E.R. Squibb & Sons, L.L.C. | $228.62 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $194.37 | 2021-2025 | |
| Leo Pharma INC. | $153.94 | 2021-2023 | Adbry |
| Dermavant Sciences, INC. | $134.94 | 2023-2024 | Vtama |
| Lilly USA, LLC | $127.61 | 2021-2025 | Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $111.00 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $84.07 | 2021-2025 | |
| Organon LLC | $80.43 | 2025 | Vtama |
| Amgen INC. | $76.23 | 2022-2025 | Otezla, Otezla |
| Pfizer INC. | $53.39 | 2021-2024 | |
| Incyte Corporation | $50.95 | 2022-2024 | Opzelura |
| Botanix Sb INC | $39.68 | 2025 | Sofdra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $35.05 | 2022-2023 | |
| Galderma Laboratories, L.P. | $34.51 | 2022-2025 | Nemluvio |
| Almirall LLC | $33.32 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.08 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.95 | 2024 | Spevigo |
| Verrica Pharmaceuticals INC. | $20.23 | 2024 | Ycanth |
| Biofrontera INC. | $18.27 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Merz North America, INC. | $13.86 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.